MEI Pharma Inc
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, … Read more
Market Cap & Net Worth: MEI Pharma Inc (MEIP)
MEI Pharma Inc (NASDAQ:MEIP) has a market capitalization of $100.81 Million ($100.81 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26082 globally and #8854 in its home market, demonstrating a -36.70% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MEI Pharma Inc's stock price $3.07 by its total outstanding shares 32837700 (32.84 Million).
MEI Pharma Inc Market Cap History: 2015 to 2025
MEI Pharma Inc's market capitalization history from 2015 to 2025. Data shows change from $816.25 Million to $100.81 Million (-19.86% CAGR).
Index Memberships
MEI Pharma Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #692 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2242 of 3165 |
Weight: MEI Pharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
MEI Pharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MEI Pharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.24x
MEI Pharma Inc's market cap is 1.24 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
4.54x
MEI Pharma Inc's market cap is 4.54 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.07 Billion | $23.25 Million | $2.67 Million | 46.08x | 401.25x |
| 2018 | $1.35 Billion | $1.62 Million | -$40.07 Million | 830.34x | N/A |
| 2019 | $1.27 Billion | $4.92 Million | -$16.82 Million | 257.41x | N/A |
| 2020 | $1.35 Billion | $28.91 Million | -$47.17 Million | 46.58x | N/A |
| 2021 | $1.36 Billion | $25.54 Million | -$41.31 Million | 53.34x | N/A |
| 2022 | $124.27 Million | $40.70 Million | -$54.45 Million | 3.05x | N/A |
| 2023 | $190.46 Million | $48.82 Million | -$31.84 Million | 3.90x | N/A |
| 2024 | $80.78 Million | $65.30 Million | $17.78 Million | 1.24x | 4.54x |
Competitor Companies of MEIP by Market Capitalization
Companies near MEI Pharma Inc in the global market cap rankings as of March 18, 2026.
Key companies related to MEI Pharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
MEI Pharma Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, MEI Pharma Inc's market cap moved from $816.25 Million to $ 100.81 Million, with a yearly change of -19.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $100.81 Million | +24.80% |
| 2024 | $80.78 Million | -57.59% |
| 2023 | $190.46 Million | +53.26% |
| 2022 | $124.27 Million | -90.88% |
| 2021 | $1.36 Billion | +1.14% |
| 2020 | $1.35 Billion | +6.45% |
| 2019 | $1.27 Billion | -6.06% |
| 2018 | $1.35 Billion | +25.71% |
| 2017 | $1.07 Billion | +45.83% |
| 2016 | $734.63 Million | -10.00% |
| 2015 | $816.25 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of MEI Pharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $100.81 Million USD |
| MoneyControl | $100.81 Million USD |
| MarketWatch | $100.81 Million USD |
| marketcap.company | $100.81 Million USD |
| Reuters | $100.81 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.